Modulation of immune checkpoint regulators in interferon γ induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics
Authors:
Open Access
- 3 May 2023
- journal article
- research article
- Published by Springer Nature in Genes & Immunity
- Vol. 24 (3) , 149-153
Abstract
Exploring the regulation of co-inhibitory (PD-1, PD-L1, CTLA-4) and co-stimulatory (CD28) genes by chemotherapeutic drugs is important for combined immune checkpoint blockade (ICB) therapy. ICB interferes with T-cell receptor and major histocompatibility complex (MHC) signaling by antibody drugs directed against the co-inhibitors. Here, we analyzed urothelial (T24) cell line with respect to cytokine signaling by interferon γ (IFNG) and the leukemia lymphocyte (Jurkat) cell line with respect to T-cell activation as mimicked by phorbolester and calcium ionophore (pma/iono). Alongside, we considered possible intervention with the chemotherapeutics gemcitabine, cisplatin and vinflunine. Noteworthy, cisplatin significantly induced PD-L1-mRNA in naïve and IFNG treated cells whereas gemcitabine and vinflunine had no effect on PD-L1-mRNA. At the protein level, PD-L1 showed typical induction in IFNG treated cells. In Jurkat cells, cisplatin significantly induced PD-1-mRNA and PD-L1-mRNA. Pma/iono administration did not alter PD-1-mRNA and PD-L1-mRNA but significantly increased CTLA-4-mRNA and CD28-mRNA levels where vinflunine suppressed the CD28-mRNA induction. In sum, we demonstrated that certain cytostatic drugs being relevant for the therapy of urothelial cancer, affect co-inhibitory and co-stimulatory modulators of immune signaling with potential impact for perspective combined ICB therapy of patients.Keywords
This publication has 21 references indexed in Scilit:
- The Interferon-Gamma Paradox in CancerJournal of Interferon & Cytokine Research, 2019
- Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profilesOncogene, 2018
- Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cellsBiomedicine & Pharmacotherapy, 2018
- Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrestPLOS ONE, 2017
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionCell Reports, 2017
- Immune checkpoints and their inhibition in cancer and infectious diseasesEuropean Journal of Immunology, 2017
- CTLA-4 and PD-1 PathwaysAmerican Journal of Clinical Oncology, 2016
- Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder CancerClinical Cancer Research, 2014
- AMP-activated protein kinase mediates T cell activation-induced expression of FasL and COX-2 via protein kinase C theta-dependent pathway in human Jurkat T leukemia cellsCellular Signalling, 2012
- Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical developmentBritish Journal of Cancer, 2002